Stocklytics Platform
Asset logo for symbol CLDX
Celldex Therapeutics
CLDX75
$43.76arrow_drop_up0.66%$0.29
Asset logo for symbol CLDX
CLDX75

$43.76

arrow_drop_up0.66%
Key Stats
Open$43.80
Prev. Close$43.47
EPS-2.75
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range42.78
44.13
52 Week Range22.11
53.18
Ratios
EPS-2.75
Fundamentals
Payout Ratio-
Industry average yield2.91%
Last Dividend pay dateFeb 11, 2019
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

CLDXarrow_drop_up0.67%
US Healthcare Sectorarrow_drop_down0.54%
US Marketarrow_drop_down1.02%
check_circle

CLDX / Market

CLDX exceeded the US Market which returned -1.02% over the last twenty four hours.
check_circle

CLDX / Healthcare Sector

CLDX exceeded the US Healthcare sector which returned -0.54% over the last twenty four hours.

Celldex Therapeutics (CLDX) Statistics

Celldex Therapeutics Inc (CLDX) is a biopharmaceutical company that focuses on the development and commercialization of novel immunotherapy products for the treatment of cancer and other diseases. The company's stock statistics reveal valuable insights into its performance in the market. One important metric is its valuation metrics, which provide an indication of the stock's worth. Investors can analyze metrics such as price-to-earnings ratio, price-to-sales ratio, and price-to-book ratio to assess the value of the stock relative to its earnings, sales, and assets respectively.
In addition to valuation metrics, it is crucial to consider the fundamentals of Celldex Therapeutics Inc. Fundamental analysis helps investors understand the underlying financial health and potential of the company. Some important fundamentals to evaluate include revenue growth, earnings per share, and return on equity. By analyzing these metrics, investors can gain insights into the company's growth prospects and profitability.
add Celldex Therapeutics  to watchlist

Keep an eye on Celldex Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Celldex Therapeutics (CLDX) stock's performance compared to its sector and the market over the past year?

Over the past year, Celldex Therapeutics (CLDX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 25.97%, Celldex Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 58.78%, it has fallen short of the market average. This comparison highlights Celldex Therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Celldex Therapeutics (CLDX) stock?

The PE ratio for Celldex Therapeutics (CLDX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Celldex Therapeutics (CLDX) stock?

The Earnings Per Share (EPS) for Celldex Therapeutics (CLDX), calculated on a diluted basis, is -$2.75. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Celldex Therapeutics (CLDX) stock?

The operating margin for Celldex Therapeutics (CLDX) is -1.85K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Celldex Therapeutics (CLDX) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Celldex Therapeutics (CLDX) is -$160.19M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Celldex Therapeutics (CLDX) have?

Celldex Therapeutics (CLDX) has a total debt of $2.38M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$40.35M.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level

Stocklytics Platform

© 2024 Stocklytics.com All rights reserved.

Stocklytics.com is not a financial advisor, and all data and information provided on this website are for informational purposes only. The content on Stocklytics.com is not intended to be a substitute for professional financial advice. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions. Stocklytics.com makes no representations or warranties regarding the accuracy, completeness, or suitability of any information provided and is not liable for any errors or omissions, or for any losses incurred as a result of reliance on the information provided on this website.

Stocklytics Discord public channelStocklytics X Social Media